| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| SI2-HF2H6 | Human | FITC-Labeled Human Siglec-2 / CD22 Protein |  |
|
|
| SI2-H525a | Human | Human Siglec-2 / CD22 Protein, Llama IgG2b Fc Tag, low endotoxin |  |
|
|
| SI2-R52Ha | Rhesus macaque | Rhesus macaque Siglec-2 / CD22 Protein |  |
|
|
| SI2-M52Ha | Mouse | Mouse Siglec-2 / CD22 Protein |  |
|
|
| SI2-H82F8 | Human | Biotinylated Human Siglec-2 / CD22 Protein, Fc Tag, Avi Tag (Avitag™) |  |
|
|
| CD2-H52H8 | Human | Human Siglec-2 / CD22 Protein |  |
|
|
| SI2-H5228 | Human | Human Siglec-2 / CD22 (176-687) Protein |  |
|
|
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Moxetumomab pasudotox | CAT-8015; GCR-8015; HA-22,CAT8015,GCR8015, HA22 | Approved | AstraZeneca | LUMOXITI | fda | ASTRAZENECA AB | 2018-09-13 | Hairy cell leukemia | Details | |
| Inotuzumab Ozogamicin | CMC-544; PF-5208773; WAY-207294,CMC544,PF5208773,WAY207294 | Approved | Pfizer, UCB | inotuzumab ozogamicin | ema | Pfizer Limited | 2017-06-29 | Acute lymphoblastic leukaemia (ALL) | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| CD22-CART | Phase Ⅰ | Shanghai Hrain Biotechnology | Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Follicular lymphoma | Details | |
| AUT-O3 | AUTO-3 | Phase Ⅱ | University College London, Autolus | B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) | Details |
| SM-03 | SM-03; SM-06 | Phase Ⅱ | Lonn Ryonn Pharma, SinoMab Bioscience Ltd | Systemic lupus erythematosus, Rheumatoid arthritis (RA), Non-Hodgkin's lymphoma (NHL) | Details |
| JCAR-018 | JCAR-018 | Phase Ⅰ | National Cancer Institute, Opus Bio, Juno Therapeutics | Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas | Details |
| BAY-1862864 | BAY-1862864 | Phase Ⅰ | Bayer | Non-Hodgkin's lymphoma (NHL) | Details |
| Epratuzumab | AMG-412; CDP-3194; IMMU-103; IMMU-1903; IMMU-hLL2,AMG412,CDP3194,IMMU103,IMMU1903,IMMUhLL2 | Phase Ⅲ | Immunomedics, UCB | Sjoegren's syndrome, Systemic lupus erythematosus, Acute lymphoblastic leukaemia (ALL) | Details |
| DT-2219-ARL | Anti-CD19-anti-CD22-diphtheria-toxin-fusion-protein; DT-2219-ARL; OXS-1550; DT-2219ARL; DT-2219; IND-100780 | Phase Ⅱ | University of Minnesota, Oxis International, GT Biopharma | B-cell lymphoma, Leukemia | Details |
| Anti-CD22/CD19 monoclonal antibody-toxin conjugate | Phase Ⅰ | University of Texas Southwestern Medical Center, Galileo Research | B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) | Details | |
| Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital) | Phase Ⅱ | General Hospital of the People's Liberation Army | B-cell lymphoma, Leukemia | Details | |
| Epratuzumab I-131 | Phase Ⅱ | Immunomedics, Repligen | Non-Hodgkin's lymphoma (NHL) | Details | |
| UCART-22 | UCART-22 | Phase Ⅰ | Cellectis | Acute lymphoblastic leukaemia (ALL) | Details |
| Pinatuzumab vedotin | DCDT-2980S; FCU-2703; RG-7593; RO-5541072; RO-5541072-000; ACD22-VCMMAE | Phase Ⅱ | Genentech | Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) | Details |
| Bectumomab | Phase Ⅲ | Immunomedics | Non-Hodgkin's lymphoma (NHL) | Details | |
| CART22-cells | CART22-cells | Phase Ⅰ | University of Pennsylvania, Novartis | B-cell lymphoma, Leukemia | Details |
| Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) | Phase Ⅰ | Stanford University | B-cell lymphoma | Details | |
| Epratuzumab Y-90 | 90Y-DOTA-hLL2; 90Y-hLL2; hCD22-Y-90; IMMU-102 | Phase Ⅱ | Immunomedics, Nantes University Hospital | Diffuse large B cell lymphoma, Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) | Details |
| Anti-CD22 monoclonal antibody-toxin conjugate (Galileo Research/the University of Texas) | IMTOX-22 | Phase Ⅰ | University of Texas Southwestern Medical Center, Royal Free and University College Medical School, Cancer Research Technology, National Institutes of Health, Galileo Research, Abiogen Pharma | Non-Hodgkin B-cell lymphomas | Details |
| CAT-3888 | CAT-3888; BL-22 | Phase Ⅱ | Cambridge Antibody Technology, National Institutes of Health, MedImmune | Lymphoblastic leukaemia, Chronic lymphocytic leukemia (CLL), Hairy cell leukemia, Non-Hodgkin's lymphoma (NHL) | Details |
| RFB4-SMPT-dgA | RFB4-SMPT-dgA; IgG-RFB4-SMPT-dgA; NSC639179 | Phase Ⅰ | National Cancer Institute, University of Texas Southwestern Medical Center | B-cell lymphoma | Details |
| TRPH-222 | TRPH-222; CAT-02-106; CD22-4AP,TRPH-222 | Phase Ⅰ | Catalent, Triphase Accelerator | B-cell lymphoma | Details |
This web search service is supported by Google Inc.
A-Z
